Series B financing

Pelage Pharmaceuticals Raises $120M to Advance Hair Loss Regenerative Therapy to Phase 3 Trials

2 weeks ago talkbio0Tagged Alopecia, Androgenetic Alopecia, Pelage, Phase 3 clinical trial, PP405, Regenerative Medicine, Series B financing, Stem Cell Therapy

Pelage Pharmaceuticals; hair loss; regenerative medicine; PP405; Phase 3 clinical trial; Series B financing; stem cell therapy; androgenetic alopecia

Kailera Raises $600 Million to Launch Global Phase III Program for Obesity Drug

2 weeks ago talkbio0Tagged Bain Capital, clinical pipeline, Funding, GLP-1/GIP Dual Agonist, Kailera, Obesity Drug, Phase 3 Clinical Trials, Series B financing, weight loss therapy

Kailera; obesity drug; Phase III clinical trial; KAI-9531; GLP-1/GIP dual agonist; Series B financing; Bain Capital; weight loss therapy; clinical pipeline; biotech funding

Ansa Biotechnologies Raises $54.4M in Series B to Scale US DNA Synthesis Manufacturing

3 weeks ago talkbio0Tagged Ansa Biotechnologies, Biotechnology, Cerberus Ventures, DNA Replication, Manufacturing, Series B financing, synthetic construct, U.S.

Ansa Biotechnologies; Series B financing; DNA synthesis; Cerberus Ventures; US manufacturing; biotechnology; synthetic DNA; fundraising

Fierce Biotech Fundraising Tracker ’25: Avenzo adds $60M Series B; Ollin debuts with $100M

1 month ago talkbio0Tagged Antibodies, Bispecific, Avenzo, Clinical Trials, Neoplasms, Ollin Biosciences, Ophthalmology specialty, pipeline development, Series B financing, venture capital

Avenzo Therapeutics; Series B financing; Ollin Biosciences; biotech fundraising; oncology; ophthalmology; venture capital; pipeline development; bispecific antibody; clinical trials

ARTBIO Raises $132M Series B to Advance Alpha Radiotherapy Pipeline and Manufacturing with Pb212

3 months ago talkbio0Tagged AB001, alpha radioligand therapies, AlphaDirect technology, ARTBIO, Cancer Therapeutic Procedure, Clinical Trials, expansion, Manufacturing, Metastatic castration-resistant prostate cancer, PB212, Series B financing

ARTBIO; Series B financing; alpha radioligand therapies; Pb212; AlphaDirect technology; cancer treatment; manufacturing expansion; AB001; metastatic castration-resistant prostate cancer; clinical trials

NUCLIDIUM Sees Copper Isotopes as Future of Radiopharmaceuticals, Raises CHF 79M to Advance Clinical Development

4 months ago talkbio0Tagged cancer diagnostics, cancer therapeutics, copper isotopes, Malignant neoplasm of breast, Metastatic Prostate Carcinoma, Neoplasms, Neuroendocrine Tumors, NUCLIDIUM, NuriPro, Radiopharmaceuticals, Series B financing, Theranostics, TraceNET

NUCLIDIUM; copper isotopes; radiopharmaceuticals; Series B financing; Cu-NuriPro; NuriPro; TraceNET; oncology; theranostics; metastatic prostate cancer; neuroendocrine tumors; breast cancer; cancer diagnostics; cancer therapeutics

Regeneron Leads $66M Series B for Actio Biosciences’ Rare Disease Therapeutics

4 months ago talkbio0Tagged ABS-0871, ABS-1230, Actio, Biosciences, Charcot-Marie-Tooth Disease, Clinical Trials, Drugs, Orphan, Epilepsy, Infrequent, Inhibitor, KCNT1 gene, Regeneron, Series B financing, TRPV4 protein, human

Regeneron; Actio Biosciences; rare diseases; Series B financing; KCNT1 inhibitor; TRPV4 inhibitor; ABS-1230; ABS-0871; Charcot-Marie-Tooth disease; epilepsy; orphan drug; clinical trials

Nuvig Therapeutics Secures $161M Series B Financing to Advance Immunomodulatory Portfolio

11 months ago talkbio0Tagged Autoimmune Diseases, Clinical Trials, Immunomodulating Agents, Nuvig, NVG-2089, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Series B financing

Nuvig Therapeutics, Series B financing, immunomodulatory drugs, autoimmune diseases, chronic inflammatory demyelinating polyneuropathy (CIDP), NVG-2089, clinical trials.